



February 14, 2022

Ms. Claudette Ransom  
Mail Stop 6628  
Securities and Exchange Commission  
100 F Street, N.E.  
Washington, DC 20549

**RE: Form 19b-4(e) – Cboe BYX Exchange, Inc.**

Ms. Ransom,

On behalf of Cboe BYX Exchange, Inc., enclosed please find one (1) executed Form 19b-4(e) and 9 copies. The enclosed Form 19b-4(e) contains information regarding four (4) derivative securities products that commenced trading on Cboe BYX Exchange on February 8, 2022. Please contact me if you any questions in connection with this matter.

Sincerely,

A handwritten signature in cursive script that reads "Kyle Murray".

Kyle Murray

VP, Associate General Counsel  
913.815.7121  
Signature executed at 10:00am on 02/14/22

For Internal Use Only  
Sec File No. 9-

Submit 1 Original  
and 9 Copies

## OMB APPROVAL

OMB Number: 3235-0504  
Expires: July 31, 2016  
Estimated average burden  
hours per response. . . . 3.60

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 19b-4(e)**

**Information Required of a Self-Regulatory Organization Listing and Trading a New  
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934**

**READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM**

**Part I Initial Listing Report**

1. Name of Self-Regulatory Organization Listing New Derivative Securities Product:  
Cboe BYX Exchange, Inc.
2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):  
See Attached.
3. Class of New Derivative Securities Product:  
See Attached.
4. Name of Underlying Instrument:  
See Attached.  22000774
5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:  
See Attached.
6. Ticker Symbol(s) of New Derivative Securities Product:  
See Attached.
7. Market or Markets Upon Which Securities Comprising Underlying Instrument  
Trades: See Attached.
8. Settlement Methodology of New Derivative Securities Product:  
Trades Locked in at Exchange and settled at NSCC.
9. Position Limits of New Derivative Securities Product (if applicable):  
Not Applicable.

**Part II Execution**

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form:  
Kyle Murray

Title:  
VP, Associate General Counsel

Telephone Number:  
913-815-7121

Manual Signature of Official Responsible for Form:  [Signature executed at 10:00am on 02/14/22]

Date:  
February 14, 2022

ATTACHMENT TO FORM 19b-4(e)  
 FOR NEW DERIVATIVE SECURITIES PRODUCTS ("NDSPs") TRADED ON CBOE BYX EXCHANGE, INC. COMMENCING ON  
 FEBRUARY 8, 2022

<b><u>(6) Ticker Symbol</u></b>	<b><u>(2) Type of Issuer of NDSP</u></b>	<b><u>(3) Class of NDSP</u></b>	<b><u>(4) Name of Underlying Instrument</u></b>	<b><u>(1) Market(s) upon Which Securities Comprising Underlying Instrument Trades</u></b>	<b><u>(5) Broad or Narrow</u></b>
PRAY	Trust	Managed Fund Shares	Equity Securities	World	N/A
LRND	Trust	Index Fund Shares	IQ U.S. Large Cap R&D Leaders Index	U.S.	Broad
MRND	Trust	Index Fund Shares	IQ U.S. Mid Cap R&D Leaders Index	U.S.	Broad
WRND	Trust	Index Fund Shares	IQ Global Equity R&D Leaders Index	World	Broad